Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
There are no side effects reported
doi: 10.1038/s41467-025-59058-w 378 WelleA.KasakowC
In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study (64) despite comparable putative GLP-1R occupancy at these doses (47)
Cost and insurance coverage newer drugs can be harder to access
Structure Therapeutics is among the most advanced challengers, with its oral GLP-1 receptor agonist aleniglipron generating Phase 2 data that has drawn significant industry attention
US$ 27.32
,aspect=ignore)
US$ 23.35
US$ 24.07
US$ 28.40
